Latest & greatest articles for osteoporosis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on osteoporosis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on osteoporosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for osteoporosis

361. Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women

Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women Education intervention designed to reduce risk factors for the development of osteoporosis and subsequent fragility fractures in post menopausal women Morley D C, Wheatley T Authors' objectives (...) To determine whether educational interventions designed to reduce risk factors for the development of osteoporosis improve compliance with risk reducing measures and improve ability to make health care decisions. Searching MEDLINE (1966-1999) and the Cochrane Library were searched (details of search strategies provided). Additional studies were identified through contacting the Cochrane Collaboration Musculo-skeletal Disease Review Group and Musculo-skeletal Injuries Sub-Group and other professionals

1999 DARE.

362. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach

The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach Amin S, LaValley M P, Simms R W, Felson D T Authors' objectives To determine if vitamin D is more effective than no therapy of calcium alone in the management of corticosteroid-induced osteoporosis, and to determine how vitamin D compares (...) with other osteoporosis therapies, e.g. bisphosphonates, calcitonin, or fluoride. Searching MEDLINE (1966-Dec 1997) and Current Contents (Oct 1997-Jan 1998) were searched (search strategy reported). Additional studies were located through searching the bibliographies of retrieved articles, and abstracts from national meetings of the ACR (1986-1997), the American Society for Bone and Mineral Research (1990-1997), and the Endocrine Society (1990-1996), as well as the European Symposium on Calcified Tissue

1999 DARE.

363. Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials

Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials Evidence-based medicine and osteoporosis: a comparison of fracture risk reduction data from osteoporosis randomised clinical trials Meunier P J Authors' objectives To assess the quality of published randomised clinical trials (...) on the treatment of osteoporosis and to specifically examine fracture risk reduction. Searching A search was conducted in MEDLINE through October 1998 for published articles in the English language. Additional articles were located through searching the bibliographies of retrieved articles. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) on osteoporosis that had examined the impact of treatment on fracture were included. Specific interventions included

1999 DARE.

364. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. (Abstract)

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. Osteoporosis is a common complication of long-term glucocorticoid therapy for which there is no well-proved preventive or restorative treatment.We carried out two 48-week, randomized, placebo-controlled studies of two doses of alendronate in 477 men and women, 17 to 83 years of age, who were receiving glucocorticoid therapy. The primary end point

1998 NEJM Controlled trial quality: predicted high

365. Bisphosphonates (alendronate and etidronate) in the management of osteoporosis

Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Bisphosphonates (alendronate and etidronate) in the management of osteoporosis Best L, Milne R Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Best L, Milne R. Bisphosphonates (...) (alendronate and etidronate) in the management of osteoporosis. Southampton: Wessex Institute for Health Research and Development (WIHRD) 1998 Authors' objectives The authors examine whether alendronate and etidronate should be used in the treatment of diagnosed osteoporosis. Authors' conclusions The authors find that the choice of target population is critical to the cost-utility of bisphosphonate treatment. If treatment is targeted towards individuals at high risk of fracture then both alendronate

1998 Health Technology Assessment (HTA) Database.

366. Exercise for female osteoporosis: a systematic review of randomised clinical trials

Exercise for female osteoporosis: a systematic review of randomised clinical trials Exercise for female osteoporosis: a systematic review of randomised clinical trials Exercise for female osteoporosis: a systematic review of randomised clinical trials Ernst E Authors' objectives To determine whether exercise is useful in the treatment and prevention of osteoporosis in women. Searching MEDLINE, EMBASE and the Cochrane Database of Systematic Reviews were each searched from their inception to 1997 (...) . Additional material was identified by searching the author's own files, by contacting other investigators in the field, and by examining the bibliographies of all studies and reviews. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) involving exercise therapy for the prevention and treatment of osteoporosis were included. There was also one study with only one group of patients (no details of the study design were provided). Specific interventions

1998 DARE.

367. Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis

Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis Cost effectiveness of multi-therapy treatment strategies in the prevention of vertebral fractures in postmenopausal women with osteoporosis Rosner A J, Grima D T, Torrance G W, Bradley C, Adachi J D, Sebaldt R J (...) women with established osteoporosis. Type of intervention Primary prevention and secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Women with established osteoporosis and who were at least 8 years postmenopausal. Setting Community. The economic study was carried out in Canada. Dates to which data relate Effectiveness data were collected from studies previously published between 1980 and 1996 and from two patient databases published

1998 NHS Economic Evaluation Database.

368. Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis

Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis Meta-analysis about efficacy of anti-resorptive drugs in post-menopausal osteoporosis Macedo J M, Macedo C R, Elkis H, De Oliveira I R Authors' objectives To compare the effect of three groups of anti-resorptive drugs in post-menopausal osteoporosis. Searching MEDLINE was searched from 1983 to 1995 (keywords given). Source (...) osteoporosis. People with senile osteoporosis or due to use of a medication or having a related disease were excluded. Outcomes assessed in the review Spine bone mass based on dual photon or dual-energy densitometry. How were decisions on the relevance of primary studies made? The authors do not state how the papers were selected for the review, or how many of the authors performed the selection. Assessment of study quality Six of the criteria specified by Chalmers et al. (1981) were used, related to size

1998 DARE.

369. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. (Abstract)

Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Small increases in bone mass are commonly seen with existing treatments for osteoporosis, which reduce bone remodelling and primarily prevent bone loss. Since these drugs reduce but do not eliminate risk of fractures, an anabolic agent that would increase bone mass and potentially cure the underlying skeletal problem is needed.We (...) did a 3-year randomised controlled trial to find out the effects of 1-34 human parathyroid hormone (hPTH [1-34], 400 U/25 micrograms daily subcutaneously) in postmenopausal women with osteoporosis taking hormone-replacement therapy (n = 17). The controls were women taking hormone-replacement therapy only (n = 17). The primary outcome was bone-mineral density of the lumbar vertebrae, with bone-mineral density at other sites and vertebral fractures as secondary endpoints.Patients taking hormone

1997 Lancet Controlled trial quality: uncertain

370. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. (Abstract)

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. Osteoporosis is a recognized complication of corticosteroid therapy. Whether it can be prevented is not known. We conducted a 12-month, randomized, placebo-controlled study of intermittent etidronate (400 mg per day for 14 days) followed by calcium (500 mg per day for 76 days), given for four cycles, in 141 men and women (age, 19 to 87 years) who had recently begun high-dose corticosteroid therapy. The primary

1997 NEJM Controlled trial quality: uncertain

371. Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy

Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy Estimating the cost per avoided hip fracture by osteoporosis treatment in Italy Visentin P, Ciravegna R, Fabris F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of calcitonin and a screening programme involving bone mass measurement to select a high risk subpopulation in the treatment of osteoporosis and the prevention of osteoporosis-induced hip fractures. Type of intervention Treatment, screening, and secondary prevention. Economic study type Cost-effectiveness analysis. Study population Women over 50 years of age and women with fractures of the proximal

1997 NHS Economic Evaluation Database.

372. Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials

Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis: a meta-analysis of published clinical trials Cardona J M, Pastor E Authors' objectives To determine the efficacy of calcitonin and etidronate in the prevention (...) of osteoporosis and osteoporotic fractures in post-menopausal women. Searching MEDLINE was searched (keywords: 'calcitonin', 'etidronate') from 1988 to 1995 for clinical trials. Reference sections of included trials and review articles were searched for other relevant trials. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) were included. Specific interventions included in the review Treatment for osteoporosis using calcitonin and etidronate medication

1997 DARE.

373. Perimenopausal bone density screening: will it help prevent osteoporosis?

Perimenopausal bone density screening: will it help prevent osteoporosis? Perimenopausal bone density screening: will it help prevent osteoporosis? Perimenopausal bone density screening: will it help prevent osteoporosis? Garton M J, Cooper C, Reid D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) that in the cost-effectiveness analysis costs were discounted by 6% while health effects were not discounted, thus effectively preventing comparison with other studies. Source of funding None stated. Bibliographic details Garton M J, Cooper C, Reid D. Perimenopausal bone density screening: will it help prevent osteoporosis? Maturitas 1997; 26(1): 35-43 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Aged; Bone Density /physiology; Climacteric /physiology; Cohort Studies; Cost-Benefit Analysis

1997 NHS Economic Evaluation Database.

374. [Use of alendronate in osteoporosis: is it cost-effective?]

[Use of alendronate in osteoporosis: is it cost-effective?] Bruk av alendronat ved osteoporose: er det kostnadseffektivt? [Use of alendronate in osteoporosis: is it cost-effective?] Bruk av alendronat ved osteoporose: er det kostnadseffektivt? [Use of alendronate in osteoporosis: is it cost-effective?] Kristiansen I S, Falch J A, Andersen L, Aursnes I Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of alendronate in the treatment of osteoporosis. Type of intervention Treatment, primary prevention and secondary prevention. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population Women with a bone mass density (BMD) less than 2.5 standard deviations below maximum BMD (the WHO

1997 NHS Economic Evaluation Database.

375. Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments

Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments Prevention of osteoporosis: cost-effectiveness of different pharmaceutical treatments Ankjaer-Jensen A, Johnell O Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Three pharmaceutical treatments programmes for osteoporosis were compared: calcium supplementation, etidronate, and calcitonin. In addition, the implementation of treatment following screening for low bone marrow density individuals was examined. Type of intervention Primary prevention; Screening. Economic study type Cost-effectiveness analysis. Study population A hypothetical cohort of women aged

1996 NHS Economic Evaluation Database.

376. Prevention of osteoporosis: a cost-effectiveness analysis regarding fractures

Prevention of osteoporosis: a cost-effectiveness analysis regarding fractures Prevention of osteoporosis: a cost-effectiveness analysis regarding fractures Prevention of osteoporosis: a cost-effectiveness analysis regarding fractures Norlund A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment (...) was clearly reported. Apparently, no systematic search of the literature was conducted for the clinical/effectiveness analysis. Source of funding None stated. Bibliographic details Norlund A. Prevention of osteoporosis: a cost-effectiveness analysis regarding fractures. Scandinavian Journal of Rheumatology 1996; 25(Supplement 103): 42-45 PubMedID Indexing Status Subject indexing assigned by NLM MeSH Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal /antagonists & Endoscopy; Female

1996 NHS Economic Evaluation Database.

377. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. Full Text available with Trip Pro

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. Postmenopausal osteoporosis is a serious health problem, and additional treatments are needed.We studied the effects of oral alendronate, an aminobisphosphonate, on bone mineral density and the incidence of fractures and height loss in 994 women with postmenopausal osteoporosis. The women were treated with placebo (...) with alendronate progressively increases the bone mass in the spine, hip, and total body and reduces the incidence of vertebral fractures, the progression of vertebral deformities, and height loss in postmenopausal women with osteoporosis.

1995 NEJM Controlled trial quality: uncertain

378. Use of calcitonin in idiopathic osteoporosis

Use of calcitonin in idiopathic osteoporosis Use of calcitonin in idiopathic osteoporosis Use of calcitonin in idiopathic osteoporosis Catalan Calcitonin Working Group Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Catalan Calcitonin Working Group. Use of calcitonin in idiopathic osteoporosis. Barcelona: Catalan Agency for Health (...) Information, Assessment and Quality (CAHIAQ -formerly CAHTA). IN95002. 1995 Authors' objectives To assess the state of knowledge regarding the efficacy, effectiveness and economic burden of intranasal calcitonin in the treatment of idiopathic osteoporosis. Authors' conclusions There is no evidence of clinical effectiveness to recommend for or against calcitonin in order to prevent osteoporotic fractures in the elderly. Although there are specific clinical situations in which calcitonin could be given

1995 Health Technology Assessment (HTA) Database.

379. Osteoporosis. Consensus statement

Osteoporosis. Consensus statement Osteoporosis. Consensus statement Osteoporosis. Consensus statement The Danish Medical Research Council and the Danish Hospital Institute Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation The Danish Medical Research Council and the Danish Hospital Institute. Osteoporosis. Consensus statement. Danish (...) Institute for Health Services Research (DSI). 1995 Authors' objectives To provide an overview of activities and problems concerning osteoporosis, and thereby forward the diffusion of expert knowledge to the public. Authors' conclusions Osteoporosis was documented to be an important social problem. Diet, physical activity and treatment with estrogen, and to some extent other drugs, reduce the loss of bone mass. With no well-documented studies of the long-term effects of the various treatments

1995 Health Technology Assessment (HTA) Database.

380. Cost-effectiveness of fracture prevention in established osteoporosis

Cost-effectiveness of fracture prevention in established osteoporosis Cost-effectiveness of fracture prevention in established osteoporosis Cost-effectiveness of fracture prevention in established osteoporosis Jonsson B, Christiansen C, Johnell O, Hedbrandt J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical (...) assessment on the reliability of the study and the conclusions drawn. Health technology Fracture prevention in established osteoporosis. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Cost-utility analysis. Study population Women aged 62 or older with osteoporosis detected. The sample was not population based. Setting Primary care. The economic study was conducted in Sweden. Dates to which data relate For the effectiveness analysis data belongs, partly

1995 NHS Economic Evaluation Database.